CTRL is engaged in the development of a next-generation platform to extract circulating tumour-reactive lymphocytes from the blood. Credit: Doodlart from Pixabay.

Biotechnology company CTRL Therapeutics has announced $10m in seed financing to boost the development of a next-generation cell therapy platform to treat solid tumours.

Led by General Catalyst, the financing round was supported by Intermountain Health, FACIT, and other investors.

Related Company Profiles

View all

The company will use the funding to further optimise and validate its technology platform, alongside expanding its team to support its initiative of offering curative therapies for cancer patients.

CTRL Therapeutics founder and chief technology officer Dr Shana Kelley said: “The field of cell therapy has been limited by the lack of tools to isolate and expand tumour-reactive cells that are efficacious against solid tumours.”

CTRL is engaged in the development of a next-generation platform to extract circulating tumour-reactive lymphocytes from blood to fill gaps linked to existing cell therapy technologies.

See Also:

The platform is being developed using inputs from tumour-infiltrating lymphocyte (TIL) therapies. It is expected to enhance the immune phenotype, quality and consistency of harvested therapeutic cells.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A study published in Nature Biomedical Engineering validated the ability of CTRL’s cell processing platform to harvest tumour-reactive immune cells from the blood.

General Catalyst partner Elena Viboch said: “CTRL combines high impact, pioneering science that harnesses natural biology with experienced leadership that is well versed in platform optimisation and clinical development.

“We are excited to partner with the CTRL team to propel the development of next-generation cellular therapy for solid tumours, and to ultimately bring accessible, safe and effective therapeutics to patients affected by cancer.”

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.